Bulk Inquiry
ARQ 197
- Tivantinib
- Soluble in DMSO
- MF: C23H19N3O2
- MW: 369.42
Description
ARQ 197 (Tivantinib) is a reported selective, non-ATP-competitive c-MET receptor tyrosine kinase inhibitor used to study HGF/MET-dependent oncogenic signaling.
MET signaling regulates tumor-cell proliferation, survival, motility and invasion, and dysregulated MET activity is associated with cancer progression and resistance. ARQ 197 is useful for interrogating MET pathway dependence in cellular oncology models.
Key Features
- Reported non-ATP-competitive c-MET inhibitor
- Targets HGF/MET receptor tyrosine kinase signaling
- Orally bioavailable oncology-relevant research compound
- Useful for studying MET-driven migration and invasion biology
Applications
- HGF/MET signaling studies
- Receptor tyrosine kinase pathway research
- Tumor cell migration and invasion assays
- Oncology pharmacology and pathway-dependence profiling
More Information
| Parent CAS No. | 905854-02-6 |
|---|---|
| Chemical Name | (3R,4R)-3-(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione |
| MFCD | MFCD11977597 |
| Short Description | c-MET inhibitor |
References
- N Munshi et al. ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity. Mol. Cancer Ther. 2010, 9, 1544-1553.
- R Bagai et al. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs. 2010, 13(6), 404-414.
- AA Adjei et al. Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist. 2011, 16(6), 788-799.
- S Eathiraj et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J. Biol. Chem. 2011, 286(23), 20666-20676.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1394 | Imatinib mesylate |
From $66.00 |
| 1398 | Sunitinib malate |
From $88.00 |
| 1414 | AG 013736 |
From $55.00 |
| 1415 | CT 53518 |
From $77.00 |
| 1419 | AB 1010 |
From $77.00 |
| 1420 | Pazopanib hydrochloride |
From $66.00 |
| 1547 | OSI 930 |
From $99.00 |
| 1581 | SU 11274 |
From $99.00 |
| 1582 | Foretinib |
From $99.00 |
| 1583 | PF 04217903 mesylate |
From $88.00 |
| 1638 | ABT 869 |
From $88.00 |
| 1660 | Crizotinib |
From $88.00 |
| 1678 | Regorafenib |
From $77.00 |
| 1696 | Quizartinib dihydrochloride |
From $99.00 |
| 1768 | AMG 706 |
From $115.50 |
| 1819 | Cabozantinib S-malate |
From $66.00 |
| 1891 | SU 6668 |
From $110.00 |
| 1914 | SGX 523 |
From $132.00 |
| 1916 | AMG 208 |
From $104.50 |
| 1959 | Golvatinib |
From $99.00 |
| 2368 | Amuvatinib |
From $132.00 |
| 2501 | Pexidartinib |
From $66.00 |
| 2553 | LY 2801653 |
From $132.00 |
| 2767 | SU11652 |
From $154.00 |
